Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

SMC

Bristol-Myers Squibb (BMS) building

BMS’ myeloma treatment accepted for priority review

If approved elotuzumab will be marketed as Empliciti

Infographic: RA Perceptions

HCPs predict the future of the biologics market

Research Partnership

Celgene building

Myeloma market set to be $9bn by 2021

New research shows it will pushed by a growing prevalence of the disease

Roche Basel Switzerland

Roche and AbbVie’s leukaemia drug set for filing by year-end

Blood cancer treatment venetoclax faces a tough market if approved

- PMLiVE

Healthcare gets more independence in Google restructuring

New ‘Alphabet’ company will put tech giant’s health ventures centre-stage

- PMLiVE

Shire makes shock $30bn bid for Baxalta

Irish firm seeking to buy the newly spun-out biotech that used to be part of Baxter

- PMLiVE

Humira gains EU licence first for Hidradenitis Suppurativa

Thirteenth licence for the drug in Europe

- PMLiVE

FDA approves four new medicines across multiple areas

Sanofi/Regeneron, BMS, AbbVie and Novartis all chalk up major approvals

- PMLiVE

AbbVie and C2N take tau antibody into clinic

Treatment being assessed for a progressive neurodegenerative disorder

- PMLiVE

Lucid wins med ed consultancy award at Communiqué

It also sees success with a professional education programme for AbbVie

- PMLiVE

Pharma set for a strong 2015 as drug sales jump

Industry looking to put the recent ‘horror’ patent expiry years behind it

- PMLiVE

NHS England sets up new £190m hep C fund

Will see patients gain access to treatments from Gilead and AbbVie

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links